HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study

Journal of the European Academy of Dermatology and Venereology

Volumn 30, Issue 6, 2016, Pages 989-994

  Kimball, A B ^a   Sobell, J M ^b   Zouboulis, C C ^c   Gu, Y ^d   Williams, D A ^d   Sundaram, M ^d   Teixeira, H D ^d   Jemec, G B E ^e  

^a HARVARD MEDICAL SCHOOL   (United States)

^b SKINCARE PHYSICIANS   (United States)

^c DESSAU MEDICAL CENTER   (Germany)

^d ABBVIE INC   (United States)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; PLACEBO;

ABSCESS; ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; GENERAL CONDITION IMPROVEMENT; HIDRADENITIS SUPPURATIVA PHYSICIAN GLOBAL ASSESSMENT SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SUPPURATIVE HIDRADENITIS; TREATMENT RESPONSE;

EID: 84983314994     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/jdv.13216     Document Type: Article

References (11)

1. Menter A, Tyring SK, Gordon K et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol 2008; 58: 106–115.
2. Fimmel S, Zouboulis CC. Comorbidities of hidradenitis suppurativa (acne inversa). Dermato-Endocrinology 2010; 2: 9–16.
3. Nazary M, van der Zee HH, Prens EP et al. Pathogenesis and pharmacotherapy of Hidradenitis suppurativa. Eur J Pharmacol 2011; 672: 1–8.
4. Adams DR, Gordon KB, Devenyi AG, Ioffreda MD. Severe hidradenitis suppurativa treated with infliximab infusion. Arch Dermatol 2003; 139: 1540–1542.
5. Hurley HJ. Hidradenitis Suppurativa. In Roenigk RK, Roenigk HH Jr, eds. Dermatologic Surgery: Principles and Practice, 2nd edn. Marcel Dekker, New York, 1996: 623–645.
6. Sartorius K, Emtestam L, Jemec GB, Lapins J. Objective scoring of hidradenitis suppurativa reflecting the role of tobacco smoking and obesity. Br J Dermatol 2009; 161: 831–839.
7. Robinson A, Kardos M, Kimball AB. Physician Global Assessment (PGA) and Psoriasis Area and Severity Index (PASI): why do both? A systematic analysis of randomized controlled trials of biologic agents for moderate to severe plaque psoriasis. J Am Acad Dermatol 2012; 66: 369–375.
8. Kimball AB, Kerdel F, Adams D et al. Adalimumab for the treatment of moderate to severe hidradenitis suppurativa: a parallel randomized trial. Ann Intern Med 2012; 157: 846–855.
9. Kimball AB, Jemec GB, Yang M et al. Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment. Br J Dermatol 2014; 171: 1434–1442.
10. Giamarellos-Bourboulis EJ, Pelekanou E, Antonopoulou A et al. An open-label phase II study of the safety and efficacy of etanercept for the therapy of hidradenitis suppurativa. Br J Dermatol 2008; 158: 567–572.
11. Sturm R. Increases in morbid obesity in the USA: 2000-2005. Public Health 2007; 121: 492–496.